Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated May 25, 2026, titled "Press Release on the audited (standalone and consolidated) financial results for the quarter and year ended March 31, 2026".
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics reported its highest-ever PAT of ₹1,014 million in FY2026, representing a 31% year-on-year growth, on consolidated revenue of ₹7,728 million. The profit includes a fair valuation gain of ₹221.75 million from investment in Apulka Healthcare Private Limited. Diluted EPS stood at ₹30.88, up 31%. Operating cash flows improved significantly to ₹1,431 million from ₹873 million in FY2025, a 64% jump reflecting structural improvements in collections and working capital management. The Board recommended a final dividend of ₹2 per share. The retail diagnostics vertical (Krsnaa Retail Private Limited) achieved an 8x revenue jump and expanded to 3,500 locations across 5 states within just 12 months.
Strong financial performance with record PAT and robust cash flow generation signals operational strength and improving business quality. The 31% PAT growth and 64% operating cash flow improvement are positive indicators for shareholders, though the fair valuation gain in PAT partially inflates the headline growth figure.